references
STRENGTHENING EXISTING CAPACITIES
Stabilization of investment in regional disease-specific networks to build capacity, conduct clinical research in endemic countries, facilitate treatment access, and disseminate information
THREE REGIONAL CLINICAL RESEARCH PLATFORMS IN ENDEMIC COUNTRIES
LEISHMANIASIS EAST AFRICA PLATFORM (LEAP) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) PLATFORM LEAP + HAT PLATFORMS CHAGAS CLINICAL RESEARCH PLATFORM (CCRP)
EXPENDITURE FOR EACH PLATFORM IN 2015 vs 2014
CHAGAS CLINICAL RESEARCH PLATFORM (CCRP)
HUMAN AFRICAN TRYPANOSOMIASIS – HAT PLATFORM
LEISHMANIASIS EAST AFRICA PLATFORM (LEAP)
2014 EUR 186 K
3 CLINICAL SITES
2015 EUR 225 K
2014 EUR 356 K
10 CLINICAL SITES in DRC and CAR
2015 EUR 263 K
2014 EUR 737 K
2015 EUR 628 K 7 CLINICAL SITES
in Bolivia and Argentina
in Ethiopia, Kenya, Sudan, and Uganda
The overall platform budgets decreased by 13% between 2014 and 2015 (from EUR 1’279 K in 2014 to EUR 1,115 K in 2015). • The Chagas platform expenditure (CCRP) increased by 21% because 2015 was a year of transition characterized by a consolidation of the main clinical research groups, with a specific agenda for each one. Consequently, the number of trainings between 2014 and 2015 increased by 129%. In addition the number of members of the platform grew by 23% (~40% of new members come from nonendemic countries) and this has a direct impact on the cost of the annual platform meeting. • The HAT platform expenditure decreased by 26% while the recruitment of the new coordinator was ongoing. Since mid-2015, with the arrival of the new coordinator of the HAT platform, the activities have fully resumed. • The Leishmaniasis East Africa platform (LEAP) costs decreased by 15%, due to the fact that the LEAP meeting was not organized together with a scientific day meeting as in 2014. LEAP continues to maintain clinical trial sites (mainly the team) even though they were not involved in R&D activities in 2015. The costs of these sites (Kimalel clinical trial site of KEMRI in Kenya, Abdu Rafi in Ethiopia, Kassab and Dooka in Sudan) were removed from R&D expenditures and allocated toward the strengthening capacities budget. Patients treated outside clinical trials in 2015 in the seven VL clinical trial sites reached 1,363 (3,910 people screened).
People trained between 2014 and 2015 increased by almost 50%
DEVELOPING RESEARCH CAPACITIES IN ENDEMIC REGIONS
In six years, platforms have been able to multiply by 7 the number of people trained every year.
1,098
LEAP HAT platform CCRP
482
736 X7 372
132 106 134
2013
275 235 226
2014
99
154
59 95
240
108 62 70
2011
316
100 131 85
2012
517
2010
2015
DNDi Annual Report 2015 › 61
2015 KEY FINANCIAL PERFORMANCE INDICATORS
